New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona, Verona, Italy; 3Allergy & Respiratory Di...
Main Authors: | Caminati M, Bagnasco D, Vaia R, Senna G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-05-01
|
Series: | Biologics: Targets & Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/new-horizons-for-the-treatment-of-severe-eosinophilic-asthma-benralizu-peer-reviewed-article-BTT |
Similar Items
-
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
by: Cristiano Caruso, et al.
Published: (2022-09-01) -
Real-life experience with benralizumab during 6 months
by: A. Padilla-Galo, et al.
Published: (2020-06-01) -
Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study
by: García-Moguel I, et al.
Published: (2022-05-01) -
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
by: Carlos Martínez-Rivera, et al.
Published: (2021-01-01) -
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
by: Corrado Pelaia, et al.
Published: (2021-12-01)